July 7, 2008 - ImmunoGen, Inc. (Nasdaq: IMGN) announced the start of patient dosing in a Phase I clinical trial evaluating the Company's IMGN388 targeted anticancer compound for the treatment of solid tumors. IMGN388 uses ImmunoGen's Tumor-Activated Prodrug (TAP) technology with an antibody that binds to an integrin target. ImmunoGen submitted the Investigational New Drug (IND) application for IMGN388 to the US Food and Drug Administration in mid-May 2008 and gained authorization to initiate clinical testing in mid-June 2008...... IMGN388 consists of the Company's DM4 cell-killing agent attached to an antibody that binds specifically to an integrin expressed on a wide range of solid tumors - melanomas, sarcomas and many carcinomas, including lung, bladder, renal cell and thyroid carcinomas... ImmunoGen's Press Release -
